Kurs
-3,29%
Kurs
-3,29%
Open
24,10
High
24,30
Low
22,90
Close
23,50
Kursutveckling under dagen för detta pressmeddelande
(NOK).
Likviditet
0,76 MNOK
Likviditet
0,76 MNOK
Rel. mcap
0,20%
Antal aktier
31 964
Likviditet under dagen för detta pressmeddelande
Kalender
Est. tid* | ||
2025-10-28 | 07:00 | Kvartalsrapport 2025-Q3 |
2025-08-14 | 07:00 | Kvartalsrapport 2025-Q2 |
2025-06-05 | N/A | X-dag ordinarie utdelning NAVA 0.00 NOK |
2025-06-04 | N/A | Årsstämma |
2025-04-30 | 07:00 | Kvartalsrapport 2025-Q1 |
2025-02-12 | - | Bokslutskommuniké 2024 |
2024-10-31 | - | Kvartalsrapport 2024-Q3 |
2024-08-16 | - | Kvartalsrapport 2024-Q2 |
2024-06-05 | - | X-dag ordinarie utdelning NAVA 0.00 NOK |
2024-06-04 | - | Årsstämma |
2024-04-30 | - | Kvartalsrapport 2024-Q1 |
2024-02-15 | - | Bokslutskommuniké 2023 |
2023-11-01 | - | Kvartalsrapport 2023-Q3 |
2023-08-11 | - | Kvartalsrapport 2023-Q2 |
2023-06-02 | - | X-dag ordinarie utdelning NAVA 0.00 NOK |
2023-06-01 | - | Årsstämma |
2023-05-11 | - | Kvartalsrapport 2023-Q1 |
2023-02-16 | - | Bokslutskommuniké 2022 |
2022-11-01 | - | Kvartalsrapport 2022-Q3 |
2022-08-12 | - | Kvartalsrapport 2022-Q2 |
2022-06-03 | - | X-dag ordinarie utdelning NAVA 0.00 NOK |
2022-06-02 | - | Årsstämma |
2022-05-10 | - | Kvartalsrapport 2022-Q1 |
2022-02-17 | - | Bokslutskommuniké 2021 |
2021-11-04 | - | Kvartalsrapport 2021-Q3 |
2021-08-13 | - | Kvartalsrapport 2021-Q2 |
2021-06-04 | - | X-dag ordinarie utdelning NAVA 0.00 NOK |
2021-06-03 | - | Årsstämma |
2021-05-11 | - | Kvartalsrapport 2021-Q1 |
2021-02-18 | - | Bokslutskommuniké 2020 |
2020-11-06 | - | Kvartalsrapport 2020-Q3 |
2020-08-20 | - | Kvartalsrapport 2020-Q2 |
2020-06-04 | - | X-dag ordinarie utdelning NAVA 0.00 NOK |
2020-06-03 | - | Årsstämma |
2020-05-14 | - | Kvartalsrapport 2020-Q1 |
2020-03-11 | - | Extra Bolagsstämma 2020 |
2020-02-13 | - | Bokslutskommuniké 2019 |
2019-11-01 | - | Kvartalsrapport 2019-Q3 |
2019-08-23 | - | Kvartalsrapport 2019-Q2 |
2019-05-29 | - | X-dag ordinarie utdelning NAVA 0.00 NOK |
2019-05-28 | - | Årsstämma |
2019-05-15 | - | Kvartalsrapport 2019-Q1 |
2019-02-14 | - | Bokslutskommuniké 2018 |
2018-12-20 | - | Extra Bolagsstämma 2018 |
2018-11-09 | - | Kvartalsrapport 2018-Q3 |
2018-08-24 | - | Kvartalsrapport 2018-Q2 |
2018-06-08 | - | X-dag ordinarie utdelning NAVA 0.00 NOK |
2018-06-07 | - | Årsstämma |
2018-05-30 | - | Kvartalsrapport 2018-Q1 |
2018-02-15 | - | Bokslutskommuniké 2017 |
2017-11-10 | - | Kvartalsrapport 2017-Q3 |
2017-07-28 | - | Kvartalsrapport 2017-Q2 |
2017-06-07 | - | X-dag ordinarie utdelning NAVA 0.00 NOK |
2017-06-06 | - | Årsstämma |
2017-05-10 | - | Kvartalsrapport 2017-Q1 |
2017-02-15 | - | Bokslutskommuniké 2016 |
2017-01-13 | - | Extra Bolagsstämma 2017 |
2016-11-11 | - | Kvartalsrapport 2016-Q3 |
2016-08-18 | - | Kvartalsrapport 2016-Q2 |
2016-06-21 | - | X-dag ordinarie utdelning NAVA 0.00 NOK |
2016-06-20 | - | Årsstämma |
2016-05-11 | - | Kvartalsrapport 2016-Q1 |
2016-02-18 | - | Bokslutskommuniké 2015 |
2015-10-30 | - | Extra Bolagsstämma 2015 |
2015-10-30 | - | Kvartalsrapport 2015-Q3 |
2015-08-21 | - | Kvartalsrapport 2015-Q2 |
2015-06-09 | - | X-dag ordinarie utdelning NAVA 0.00 NOK |
2015-06-08 | - | Årsstämma |
2015-04-28 | - | Kvartalsrapport 2015-Q1 |
2015-02-27 | - | Bokslutskommuniké 2014 |
2014-10-31 | - | Kvartalsrapport 2014-Q3 |
2014-08-22 | - | Kvartalsrapport 2014-Q2 |
2014-06-10 | - | Årsstämma |
2014-05-06 | - | Kvartalsrapport 2014-Q1 |
2014-02-27 | - | Bokslutskommuniké 2013 |
2013-11-01 | - | Kvartalsrapport 2013-Q3 |
2013-08-30 | - | Kvartalsrapport 2013-Q2 |
2013-06-13 | - | Kapitalmarknadsdag 2013 |
2013-05-23 | - | Årsstämma |
2013-04-25 | - | Kvartalsrapport 2013-Q1 |
2013-02-15 | - | Bokslutskommuniké 2012 |
2012-02-10 | - | Bokslutskommuniké 2011 |
2011-10-21 | - | Kvartalsrapport 2011-Q3 |
2011-08-25 | - | Kvartalsrapport 2011-Q2 |
2011-05-05 | - | Kvartalsrapport 2011-Q1 |
2011-04-14 | - | Årsstämma |
2011-02-04 | - | Bokslutskommuniké 2010 |
2010-10-28 | - | Kvartalsrapport 2010-Q3 |
2010-08-26 | - | Kvartalsrapport 2010-Q2 |
2010-05-05 | - | Kvartalsrapport 2010-Q1 |
2010-03-25 | - | Årsstämma |
2010-02-11 | - | Bokslutskommuniké 2009 |
Beskrivning
Land | Norge |
---|---|
Lista | Oslo Bors |
Sektor | Hälsovård |
Industri | Läkemedel & Handel |
2021-05-07 14:22:51
Oslo 7 May 2021 - Navamedic ASA ("Navamedic", OSE: NAVA) announces it has signed
an agreement with Icepharma for distribution of the antibiotics products to the
Icelandic market.
As announced on 4 August 2020, Navamedic completed the acquisition of marketing
authorisations in the Nordics for a portfolio of antibiotics products. The
antibiotics in the portfolio, now fully onboarded on Navamedic's platform, are
designed to be given intravenously to patients and are in regular use in
hospitals in all the Nordic countries.
In accordance with the plan to roll out antibiotics in the Nordic region,
Navamedic has signed an agreement with Icepharma for distribution of the
antibiotics products to the Icelandic market.
"The addition of the antibiotics portfolio marked an important milestone for
Navamedic and our expanding hospital and prescription drug offering. We are
pleased to welcome Icepharma to join us in securing steady supply of these
important products to Nordic hospitals," says Kathrine Gamborg Andreassen, CEO
of Navamedic.
The antibiotics in the portfolio are designed to be given intravenously to
patients and are currently in regular use in hospitals in all the Nordic
countries with an annual turnover of approximately NOK 25 million. This
portfolio will strengthen NavamedicŽs hospital offering with an important
product range. This is an important step in NavamedicŽs growth strategy.
Navamedic has recruited Janne Folmoe to the company's Specialty Pharma
commercial team. Folmoe comes with extensive experience from the ACS Dobfar
portfolio with focus on tender management, and previous commercial positions in
the pharma industry in companies such as Bayer and Mylan. Folmoe will play a key
role in the commercial operation with regards to the antibiotics portfolio.
For more information, please contact:
Kathrine Gamborg Andreassen, CEO of Navamedic ASA
kathrine@navamedic.com
Alexander Lidmejer, Commercial Director Specialty Pharma at Navamedic ASA
+46 70 257 99 71
alexander.lidmejer@navamedic.com
About Navamedic
Navamedic ASA is a Nordic pharma company and reliable provider of high-quality
products, delivered to hospitals and through pharmacies, meeting the specific
needs of patients and consumers by leveraging its highly scalable market access
platform, leading category competence and local knowledge. Navamedic is present
in all the Nordic countries, the Baltics and Benelux, with sales representation
in the UK and Greece. Navamedic is headquartered in Oslo, Norway, and listed on
the Oslo Stock Exchange (ticker: NAVA). For more information, please visit
www.navamedic.com